Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Genetic Testing

Should UGT1A1 Genotyping Be Used to Predict Response to Irinotecan Chemotherapy?
EGAPP™ Recommendation

 

Background

Irinotecan is a drug that is often used in combination with other chemotherapy agents to treat colorectal cancer that has spread to other parts of the body (metastatic).  Certain changes in a gene known as UGT1A1 have been found to affect how quickly a person’s body metabolizes (changes) irinotecan from its active to inactive form.  This could impact how much of the drug should be used (dosing), and the type and severity of side effects a person might experience. 

Patients metabolize (or process) drugs differently because of a variety of factors. Variations in genes may be one reason why some people metabolize certain drugs well and other people do not. The EGAPP™ Working Group examined the scientific evidence to see whether UGT1A1 genotyping is valid and useful for guiding irinotecan dosing in the management of patients with metastatic colorectal cancer to improve effectiveness and reduce side effects.



EGAPP™ Recommendation Statement


Summary of Findings on UGT1A1 Genotyping to Predict Response to Irinotecan

In 2009, the independent Evaluation of Genomic Applications in Practice and Prevention (EGAPP™) Working Group evaluated the use of UGT1A1 genotyping to determine the best dose of irinotecan to prevent side effects when treating patients with metastatic colorectal cancer. The Working Group determined that there was not enough evidence to conclude whether UGT1A1 genotyping should be used for this purpose. The balance of benefits and harms of UGT1A1 genotyping to guide irinotecan use could not be determined from the available evidence.

The EGAPP recommendation statement was based on the following key points from the evidence review:

  • UGT1A1 genotyping results appear accurate for the common variants.
  • Observational studies identified associations between UGT1A1 genotype results and the occurrence of certain side effects, as well as a potential impact on treatment effectiveness.
  • The EGAPP Working Group (EWG) found no evidence that demonstrated that targeted dosing of irinotecan based on UGT1A1 genotyping leads to improved patient outcomes.
  • Even if targeted dosing were shown to be highly effective, it is not clear that benefits (reduced side effects) would outweigh harms (unresponsive tumors).

For the General Public

Should UGT1A1 Genotyping be Used to Predict Response to Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer?


For Health Professionals

More about the EGAPPTM UGT1A1 Genotyping Recommendation

Public Health Implications of UGT1A1 Genotyping and Use of Irinotecan Chemotherapy for Metastatic Colorectal Cancer



Disclaimer:
Our office does not offer medical advice to individuals. If you have specific concerns about your health, please discuss them with your doctor.


Neutropenia
Neutropenia is an abnormally low count of neutrophils, white blood cells that protect your body from bacteria and fungi. The lower your neutrophil count, the more vulnerable you are to infectious diseases.

Definition adapted from Mayo Clinic.com.

 

Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd. Atlanta, GA 30333 USA
    800-CDC-INFO (800-232-4636)
  • Additional information for Public Health Genomics is available on our contact page.
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #